Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line
Sanofi has licensed rights to Kali’s trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
FDA seeks public input on controversial priority voucher scheme amid concerns about its transparency and legality.
Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results.
Monday’s Phase 2 maintenance data highlighted the efficacy of …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844